Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .
Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.

Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients